Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

iOpeners

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic retinopathy

REGENXBIO launches phase 2b/3 trial of sura-vec for diabetic retinopathy

Q&A: Understanding the influences on molecular confirmation after genetic testing for IRDs

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Somerset, NJ-MedPointe Inc. has acquired all U.S. and Canadian rights to azelastine HCl (Optivar), a treatment for itching of the eye associated with allergic conjunctivitis in adults and children ages 3 and older.

MedPointe to sell drug for itchy, allergic eyes

MedPointe to sell drug for itchy, allergic eyes

Newsletter